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Dietary boron intake does not change the ischemic tolerance
and preconditioning response in isoproterenol-induced
myocardial injury in healthy rats
Mehmet Fatih KARAKAŞ1, Mustafa KURT2, Uğur ARSLANTAŞ3, Göktürk İPEK4, Esra KARAKAŞ,5
Emine BİLEN6, Hüsamettin ERDAMAR7

Aim: Boron is important for many enzymes, most of which also have a role in the ischemic tolerance of the myocardium.
We aimed to evaluate the influence of dietary boron intake on ischemic tolerance in a rat model.
Materials and methods: Rats were divided into 3 groups according to the ischemia protocol: Sham (S) (n = 20 total),
ischemia only (Isc-only) (n = 40 total), and remote ischemic preconditioning + ischemia (RIPC+Isc) (n = 40 total)
groups. These 3 groups were further divided into 4 according to the amount of daily dietary boron (<1 mg/kg, 2 mg/kg,
13 mg/kg, and 100 mg/kg). After 4 weeks of this diet, the rats were operated on, and baseline hemodynamic data and
postoperative blood serum were obtained.
Results: Troponin I (Tn I) levels were lower in the RIPC+Isc group than in the Isc-only group (P < 0.01), whereas Tn I
levels were not different among the dietary groups (P = 0.725). The Tn I levels were higher in the RIPC+Isc and in the
Isc-only group than in the S group (P < 0.001 and P < 0.001, respectively).
Conclusion: Boron in diets did not influence the extent of myocardial injury in the groups. Furthermore, dietary boron
does not deteriorate the response of the most potent endogenous mechanism of the heart against ischemia.
Key words: Boron, ischemia, ischemic preconditioning, cardioprotection, murine model, myocardial injury

Introduction
Throughout the world, ischemic heart disease
is the leading cause of mortality and morbidity
(1). Much effort is being spent on understanding
and improving the mechanisms that enhance the
ischemic tolerance of the heart. In this particular
study, we hypothesized that boron may be a part
of the endogenous protective responses of the
ischemic myocardium, due to the fact that boron, a

widely accessible trace element, is important in the
function of many different enzymes, such as steroid
hormones, oxidoreductases, and hydroxylases, most
of which also have a role in the ischemic tolerance
and the ischemic preconditioning response of the
myocardium (2). However, there are no data on the
effects of boron on ischemic myocardium, neither in
humans nor in animal models. The aim of this study
is to evaluate the influence of dietary boron intake on
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ischemia and ischemic preconditioning response in
an experimental rat model. After an ischemic episode,
a temporary loss of contractile function occurs,
a process referred to as ‘stunning’ (3). Repetitive
periods of ischemia on stunning myocardium lead
to a prolonged postischemic left ventricular (LV)
dysfunction known as hibernation (4). Hibernation is
actually an endogenous protective mechanism, which
is thought to occur via altered flow/function relation,
metabolic adaptation, alteration of Ca2+ homeostasis,
changes in mechanisms of cell death, or autophagy
(5). Because quality of life and mortality are closely
related to the amount of functional myocardium
after ischemia, anything that enhances the ischemic
tolerance of the heart is of great clinical importance
(6). Ischemic preconditioning, a term used to define
the diminished degree of vulnerability of the heart
to prolonged ischemic episodes after brief, repetitive
periods of ischemia, is by far the most powerful
endogenous protective mechanism against ischemic
insult (3). Boron has been accepted as a trace element
for plants since 1923 (7). The importance of modulator
effects of boron on animal systems was discovered
in the late 1980s (8). Despite its being known as a
cofactor of 26 different enzymes regulating energy
metabolism, steroid hormones, immune system,
coagulation system, hydroxylation, and oxidation–
antioxidation reactions (2), very little is known about
the influence of boron on cardiovascular system
hemodynamics. Isoproterenol (ISO), a synthetic
catecholamine and beta-adrenergic agonist, is a wellknown agent and is widely used to induce myocardial
injury in experimental models (9,10). For the first
time in medical literature, we aimed to study the
effects of dietary boron on the extent of injury and
the remote ischemic preconditioning response in an
ISO-induced myocardial injury model.
Materials and methods
Study design
The present study was a prospective, controlled
animal laboratory study.
Animals
Male Sprague–Dawley rats, 14–16 weeks of age
(250–500 g), were used for the experiments. The
experiments were conducted in parallel to the ethical

norms of the local ethics committee. All animals were
fed with a special basal diet and distilled water, and
a certain amount of supplementary boron was given
with orogastric gavage, according to the experimental
group. The animals were kept in standard laboratory
conditions under natural light and dark cycles.
They were free to access water and food during the
experimental period.
Study protocol
Male Sprague–Dawley rats, 14–16 weeks of age (n
= 100), were divided into 3 groups according to the
ischemia protocol: Sham (S) (n = 20 total), ischemia
only (Isc-only) (n = 40 total), and remote ischemic
preconditioning + ischemia (RIPC+Isc) (n = 40 total)
groups. These 3 groups were further divided into 4
groups according to the amount of boron supplied in
their daily diet (<1 mg/kg, 2 mg/kg, 13 mg/kg, 100 mg/
kg) (S group: n = 20 total, 5 for each diet group; Isc-only
group: n = 40 total, 10 for each diet group; RIPC+Isc:
n = 40, 10 for each diet group). The “boron < 1 mg/kg”
group was given saline, and the other groups (boron = 2
mg/kg, 13 mg/kg, and 100 mg/kg) were given additional
supplementary boron by orogastric gavage. After 4
weeks of the diet, the experiments were conducted.
Fourteen rats died before the experiments started. Ten
of these 14 rats were from the 100 mg/kg boron group,
3 rats belonged to the 13 mg/kg group, and 1 was from
the group receiving <1 mg/kg boron. We weighed all
the animals regularly and observed weight loss, fatigue,
and decreased appetite in some of the animals receiving
100 mg/kg boron. We think that this observation,
which was consistent with the symptoms seen in boron
toxicity such as decreased appetite, weight loss, and
the deaths in the 100 mg/kg boron group, might be
associated with excess boron intake. For the animals
that died, we performed autopsies and we did not detect
any remarkable findings.
Following the administration of anesthesia using
ketamine–xylazine, animals were placed on heating
pads. The core temperature was measured using
a rectal probe and was maintained at 37 °C. The
right carotid artery was cannulated, and a Millar
microtip pressure–volume conductance catheter
was placed into the left ventricular apex in order
to take hemodynamic data. After hemodynamic
stabilization, the S group was vehicle-operated; in
the Isc-only group, 150 mg/kg ISO, administered
1371
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subcutaneously (s.c.), was used to induce myocardial
ischemia, and in the RIPC+Isc group, after 3 sets of
5 min of ischemia/reperfusion via femoral artery to
induce RIPC, 150 mg/kg ISO was administered s.c.
In all groups, hemodynamic data were collected
at baseline. Four hours after ISO administration,
blood samples were obtained and animals were
euthanatized. During experiments, 15 rats had a
mean arterial pressure (MAP) of <70 mmHg for
more than 10 min or developed sustained ventricular
tachycardia (VT)/ventricular fibrillation (VF) and,
therefore, were excluded from the study.
Drugs and chemicals
Rats were fed with a special basal diet and distilled
water with reduced boron content (<1 mg/kg) (BilTek Ltd., Ankara, Turkey) (Table 1). The boron
analysis of the basal diet was performed at the METU
and TÜBİTAK MAM laboratories. Supplementary
boron was provided by Hacettepe University (Ankara,

Turkey) as boric acid. ISO was purchased from Sigma
Chemicals (Germany).
Hemodynamic measurements
By the aid of the data gathered with the Millar
microtip pressure–volume conductance catheter,
heart rate (HR), LV systolic pressure (LVSP), LV
end-diastolic pressure (LVEDP), MAP, maximum
pressure development (dP/dtmax) and minimum
pressure development (dP/dtmin), ejection fraction
(EF), stroke volume (SV), end-diastolic volume
(EDV), end-systolic volume (ESV), and stroke work
(SW) were calculated with LabChart 7.2 software
(AD Instruments, UK) for the comparison of
baseline values among groups. To correct for cardiac
mass volume, saline calibration was done and parallel
conductance volume (Vp) was calculated. Cuvette
calibration was performed to turn the raw signal
acquired by the conductance catheter into absolute
volume.

Table 1. Chemical composition of basal diet (Bil-Tek Ltd., Turkey).
Analysis

%

Vitamins

/kg

Minerals

/kg

Dry matter

93.00

Vitamin A

75,000 IU

Manganese

400 mg

Crude protein

45.00

Vitamin D3

20,000 IU

Iron

300 mg

Crude cellulose

3.00

Vitamin E

500 mg

Zinc

300 mg

Crude ash

10.00

Vitamin K3

12.5 mg

Copper

25 mg

Crude lipid

2.00

Vitamin B1

12.5 mg

Iodine

5 mg

Methionine

2.00

Vitamin B2

35 mg

Cobalt

1 mg

Lysine

3.50

Niacin

300 mg

Selenium

0.75 mg

Calcium

2.50

Cal. D-pantothenate

60 mg

Phosphorus

2.00

Vitamin B6

20 mg

Cystine

0.50

Vitamin B12

100 mg

Potassium

1.60

Folic acid

5 mg

Linoleic acid

1.00

D-biotin

0.5 mg

Tryptophan

0.50

Choline chloride

Sodium

0.10

Meth+Cystine

2.50

Arginine

3.0

Threonine

1.60
Metabolic energy (kcal/kg): 2750
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Biochemical assays

Results

For the detection of the extent of myocardial necrosis,
troponin I (Tn I) levels were measured with a Centaur
XL autoanalyzer (Siemens, USA). The measurements
were expressed as ng/mL for Tn I (normal range:
0.00–0.99 ng/mL; interassay and total % covariance
values were 2.1 and 2.9, respectively).

Analysis of the data gathered with the Millar microtip
pressure-volume conductance catheter revealed that
there were no significant differences among groups in
terms of LV systolic indices (Table 2). The Tn I levels
were significantly lower in the RIPC+Isc group than
in the Isc-only group (23.3 ± 8.2 vs. 28.8 ± 9.3; P <
0.01) (Figure 1), whereas Tn I levels were not different
among the diet groups (24.4 ± 27.8 vs. 21.6 ± 25.9 vs.
26.7 ± 24.5 vs. 22.9 ± 14.2; P = 0.725) (Figure 2 and
Table 3). The Tn I levels were significantly higher in
the experimental groups than in the S group (23.3 ±
8.2 vs. 0.64 ± 0.6, P < 0.001; 28.8 ± 9.3 vs. 0.64 ± 0.6,
P < 0.001) (Figure 1).

Statistical analysis
After normality tests were conducted, results were
expressed as median ± interquartile range (IQR) for
all groups. Statistical analysis was performed with
SPSS 17.0 (SPSS Inc., USA). For the hemodynamic
parameters and Tn I results, comparison between
the groups was done using the Kruskal–Wallis test.
Further analysis of the difference between 2 groups
was done using the Mann–Whitney U test with
Bonferroni correction. P < 0.05 was accepted as
significant for comparison between all groups, and P
< 0.016 was accepted as significant for comparison
between 2 groups.

Discussion
According to our results, for the first time in the
medical literature, it is shown that the amount
of dietary boron does not affect the baseline LV
systolic indices or the extent of myocardial injury

Table 2. Baseline hemodynamic values of dietary groups.
< 1 mg/kg
(n = 19)

2 mg/kg
(n = 18)

13 mg/kg
(n = 20)

100 mg/kg
(n = 14)

HR, bpm

377 ± 19

395 ± 21

374 ± 38

387 ± 24

MAP, mmHg

100 ± 12

99 ± 15

97 ± 15

93 ± 11

LVSP, mmHg

122 ± 15

131 ± 18

118 ± 19

127 ± 7

LVEDP, mmHg

11 ± 5

10 ± 5

12 ± 4

8±6

EF, %

55 ± 7

59 ± 7

52 ± 7

54 ± 7

LV dP/dtmax, mmHg/s

9149 ± 1141

8850 ± 1006

10,115 ± 1240

8495 ± 1855

LV dP/dtmin, mmHg/s

9467 ± 1309

9752 ± 1383

8900 ± 1543

9504 ± 1416

EDV, µL

308 ± 41

270 ± 46

287 ± 45

303 ± 31

ESV, µL

221 ± 42

211 ± 38

244 ± 19

233 ± 25

SV, µL

138 ± 8

139 ± 12

129 ± 15

133 ± 15

12,221 ± 1109

10,841 ± 1798

13,022 ± 1671

11,394 ± 1881

SW, mmHg × µL

dP/dtmax, maximum pressure development; dP/dtmin, minimum pressure development; EDV, end-diastolic volume; EF, ejection
fraction; ESV, end-systolic volume; HR, heart rate; LVSP, maximal LV pressure; LVEDP, LV end-diastolic pressure; MAP, mean arterial
pressure; SV, stroke volume; SW, stroke work.
All values are expressed as median ± IQR. Comparison between all groups was done with the Kruskal–Wallis test and there were no
significant differences between groups in any of the parameters (P > 0.05 for all).
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Troponin I
50
45
40
35
30
25
20
15
10
5
0
<1 2

13 100

Sham group

<1 2

13 100

Ischemia group

<1 2

13 100

RIPC+ISC group

<1 2

13 100

All groups

Figure 1. The mean troponin I levels between groups according to ischemia protocol.
Values are given as median ± IQR. IQR: interquartile range, RIPC: remote
ischemic preconditioning, Tn I: troponin I. There are no significant differences
between dietary boron groups (P = 0.725).

Troponin I
50
45
40
35
30
25
20
15
10
5
0
S Isc-only RIPC+Isc S Isc-only RIPC+Isc
<1mg/kg group
2 mg/kg group

S Isc-only RIPC+Isc
13 mg/kg group

S Isc-only RIPC+Isc
All groups

Figure 2. The mean troponin I levels between groups according to dietary boron
groups. Values are given as median ± IQR. IQR: interquartile range, RIPC:
remote ischemic preconditioning, Tn I: troponin I. The sham group was
significantly different from the Isc-only and RIPC+Isc groups (P < 0.001),
and the differences between the Isc-only and RIPC+Isc groups were found to
be significant (P < 0.001).

after myocardial insult, and that the mitigation of
myocardial injury provided by RIPC in the early
phase is protected and not deteriorated by the amount
of dietary boron.
Cardiovascular disease is the leading cause of
death throughout the world. In the setting of acute
coronary syndromes, the primary goal is to restore
the abrupt cessation of blood flow in order to salvage
ischemic tissue before it is irreversibly injured,
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which in turn leads to improved residual ventricular
function and clinical outcomes (6). However,
reperfusion itself causes cell death, a process referred
to as reperfusion injury (6). In clinical practice,
the unpredictable nature of the onset of ischemia
limits the usage of experimental interventions to
those shown to be effective against ischemia. Most
studies aim to discover the answer to the ultimate
question of how the resistance of heart tissue can
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Table 3. Effect of dietary boron on serum troponin I levels after isoproterenol-induced myocardial injury in rats.
Groups

<1 mg/kg

2 mg/kg

13 mg/kg

100 mg/kg

Troponin I
Sham (n = 5)

0.62 ± 0.47

Isc-only (n = 7)

28.7 ± 8.3

RIPC+Isc (n = 7)

24.4 ± 8.4

Total (n = 19)

24.4 ± 27.8

Sham (n = 5)

0.73 ± 0.37

Isc-only (n = 7)

25.5 ± 6.4

RIPC+Isc (n = 6)

23.8 ± 9.8

Total (n = 18)

21.6 ± 25.9

Sham (n = 5)

0.52 ± 0.6

Isc-only (n = 7)

31.1 ± 8.9

RIPC+Isc (n = 8)

24.5 ± 7.9

Total (n = 20)

26.7 ± 24.5

Sham (n = 3)

0.87 ± 0.32

Isc-only (n = 5)

31.1 ± 17.3

RIPC+Isc (n = 6)

21.6 ± 7.0

Total (n = 14)

22.9 ± 14.2

P

0.752

0.752

0.752

0.752

Each value is median ± IQR in each group, and all group comparisons were done with the Kruskal–Wallis test. There were no significant differences between the dietary boron groups (P = 0.725).

be improved in ischemia and reperfusion injury. In
1986, a preliminary work showed that brief episodes
of ischemia and reperfusion make the heart more
resistant to ischemia, a process referred to as ischemic
preconditioning (IPC) (3). This paradigm has been
studied by many researchers in order to understand
the mechanisms that improve ischemic tolerance
(11–13). In other words, this paradigm implied that
myocardial protection against ischemia is possible
and that these mechanisms may be translated into
clinical practice. The paradigm of IPC was extended
to such a degree that brief ischemia in an organ that
is distant or remote from the heart, such as the limbs,
intestine, kidney, or skeletal muscle, also protects the
heart against ischemia. This phenomenon is known
as RIPC (14,15). There are many models for RIPC
induction applied in different species with different

RIPC protocols and RIPC sites. Kharbanda et al.
produced hind-limb ischemia with 5-min cycles of
ischemia and reperfusion in pigs (14). In another
report, Kristiansen et al. produced RIPC via 5-min
cycles of ischemia and reperfusion using limbs as the
RIPC site in rats (16). In our particular study, we chose
the femoral artery as the RIPC site and 5-min cycles
of ischemia and reperfusion as the RIPC protocol.
Furthermore, cycles of intermittent limb ischemia
provide an acceptable method for cardioprotection,
which, when used, was shown to be effective with
reduced cardiac injury markers in cardiac surgery
and in coronary angioplasty, as well (17–19). Tn I is
closely related with the severity of myocardial injury
(20). Because it is a sensitive marker of myocardial
injury, we used Tn I to detect the change in the extent
of myocardial injury with different experimental
1375
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protocols. In our experimental setting, we used ISO
to induce myocardial ischemia and the formation
of myocardial infarction, such as lesions, which is
widely used in toxicology studies (9,10). In the rat,
at high doses, ISO stimulates beta-1 and beta-2
receptors, resulting in an abnormally high heart rate
and reduced blood pressure. As a result of an oxygen
demand–supply mismatch, anoxia/hypoxia occurs in
cardiac tissue (10). These changes are closely related
to elevation of serum cardiac Tn, which shows the
extent of myocardial injury (20). The elevations in
the levels of serum Tn become evident within 4 h of
drug administration, and levels of cardiac Tn show
a gradual decline from 4 to 24 h after dosing (21).
Thus, we obtained hemodynamic data and tissue
samples at 4 h after ISO administration. IPC has
been shown to have 2 protection phases; the “early”
IPC or “first window” protects the heart for 1 or 2
h and then wanes, and the “late” IPC or ”second
window of protection” appears 24 h after the first IPC
protocol and lasts for 24–48 h (22,23). Obtaining the
hemodynamic data and tissue samples in the very
first hours of ischemia seems rational to evaluate
the first phase responses of IPC. On the other hand,
this is a limitation of our study, because what we
found reveals only information on the “early” phase
of IPC, not the “late” IPC. Moreover, the evaluation
of “late” IPC response with this protocol would be
inappropriate, because there are some data present on
ketamine deteriorating the late IPC response (24,25).
Boron was accepted in 1923 as an essential element
for all vascular plants (7). However, the importance
of boron for humans and animals seems to have
been overlooked until the 1980s (8). Being the fifth
element and the only nonmetal in the Group IIIA
elements, boron contains both metal and nonmetal
characteristics (26). Boron is commonly found in
nature in the form of borates, is accessible to all plants
and animals, is absorbed 100% across the mucous
membranes by humans and animals, and is excreted
mostly in the urine (2,27–29). The primary sources
are fruits and vegetables, whereas animal sources
provide lower amounts of boron (30). The assessment
of boron intake is difficult because there is no national
database showing the amount of boron present in
foods and personal care products (31). Because
boron is widely accessible, deficiency is not common;
however, boron deficiency may cause abnormal
1376

bone growth or impaired growth and exacerbate the
deficiency symptoms of vitamin D3, whereas boron
toxicity shares similarities to pellagra symptoms
(8,26,32). In the case of chronic toxicity, poor appetite,
nausea, weight loss, and decreased seminal volume
and sexual activity are seen (32). Although adult
doses of 18 to 20 mg of boron have been shown to be
fatal, death from boron toxicity is unusual (32). The
World Health Organization suggests a daily intake of
2 mg of boron, whereas the minimum daily dosage
reported for the “lowest-observed-adverse-effect
level” (LOAEL) is 13–13.6 mg/kg (33,34). Therefore,
in our experiments, we gave the rats 2 mg/kg and
13 mg/kg of boron daily to observe the influence of
a physiologic dose of boron on ischemic heart tissue.
Boron is able to interact with important biological
substances, including polysaccharides, pyridoxine,
riboflavin, dehydroascorbic acid, and pyridine
nucleotides (28). Hunt reported that boron influences
the activity of at least 26 different enzymes seen in
animal, plant, cultured, and chemical reaction systems
(2). Boron plays a role in regulating enzymatic activity
in pathways involved in energy substrate metabolism,
insulin release, nucleic acid synthesis, and the immune
system (2). Serine proteases and oxidoreductases
require pyridine or flavin nucleotides (nicotinamide
adenine dinucleotide [NAD+], nicotinamide adenine
dinucleotide phosphate [NADP], and flavin adenine
dinucleotide [FAD]), and boron reversibly inhibits
their activities by competing for NAD or FAD (2).
Boron also inhibits glycolytic enzyme activity in
vitro and modifies insulin release by altering the
metabolism of NADPH. Boron may also lower the
level of oxidative damage, which is accomplished by
decreasing the production of NADPH and the activity
of delta-glutamyl transpeptidase (2). Although the
influences of boron in steroid hormone metabolism,
calcium metabolism, bone development, and energy
metabolism are known to a degree, there is no report
regarding the effects of boron on ischemic heart tissue.
Contractile dysfunction after ischemia is thought to
be related to changes in metabolic pathways, alteration
of calcium homeostasis and energy metabolism, and
changes in cell death mechanisms, all of which are
somehow related to boron, as mentioned above (5).
With this particular study, we aimed to examine the
possible effects of boron on ischemic heart tissue
for the first time in medical literature. According to
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our results, the amount of dietary boron does not
affect the baseline LV systolic indices or the extent
of myocardial injury after the myocardial insult. The
mitigation of myocardial injury provided by RIPC
in the early phase is protected and not deteriorated
by the amount of dietary boron. However, there is
no significant difference between ischemia and IPC
groups in terms of dietary amount of boron. Our diet
was not lacking in calcium or magnesium, and in the
boron-deficient group the amount of boron supplied
was around 1 mg/kg. One possible reason for this may
be that, as emphasized in the literature, the effects
of boron become more pronounced where there is a
lack of calcium or magnesium. Another possibility
is that, because boron is a trace element, very small
amounts in the diet may mask the effects of absolute
boron deficiency on early IPC response. It should also
be kept in mind that the pronounced effects of boron
were shown in disease conditions such as diabetes,
postmenopause, and rachitism models (35). The
effects of boron on IPC response in disease conditions
need to be investigated.
In this study, we aimed to examine the possible
effects of boron on ischemic heart tissue for the
first time in the medical literature. According to

our results, the amount of dietary boron does not
affect the baseline LV systolic indices or the extent
of myocardial injury after the myocardial insult. The
mitigation of myocardial injury provided by RIPC in
the early phase is protected and not deteriorated by
the amount of dietary boron.
As mentioned above, our diet contained around
1 mg/kg boron and was not lacking in calcium and
magnesium, an occurrence that may mask the effects
of absolute boron deficiency. There are data available
regarding the process of ketamine deteriorating the
late IPC response, but this cannot be considered as
a limitation, because we evaluated the “early” IPC
response; however, evaluating only the “early” IPC
response may be a limitation of the present study,
because in order to comprehend the IPC response
mechanisms, “late” IPC responses should be
evaluated, as well. Lastly, if more subjects had been
included in the subgroups, our results would have
been more precise and appropriate.
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